AI & Pharma: Start Small But Think Big

Posted by Arun Shastri on Wed, Jul 24, 2019

This blog post is the first in a series on the impact that AI will have on different business aspects of pharma.

AI has been here for many decades, but the buzz around this latest wave of AI is louder than any I can remember. You can find articles about AI in every publication and medium. These articles deal mostly with broad themes, rarely delving into how AI might be applied in our work lives. There are plenty of stories about self-driving cars and the latest human expert to be outwitted by an algorithm. But what about the unsexy business that most of us find ourselves in? How can we apply AI to improve customer interactions, maximize product launches, optimize clinical trial operations, or find patient insights?


>
Read More

The Evolving Data Landscape Will Transform Healthcare. Here Are Four Trends to Watch.

Posted by Paul Darling on Fri, Jun 28, 2019

Oladele Ojo co-wrote this blog post with Paul Darling. 

The healthcare system generates approximately a zettabyte (a trillion gigabytes) of data each year, which includes both classic data from sources such as EHRs, diagnostics and genetics, as well as newer data sources such as gut biome sensors, wearable devices and environmental monitors, and social media. Consequently, it’s now possible to quantify a person across three dimensions of human existence: biological, environmental and digital/social.


>
Read More

First Launch Commercialization Strategy: Go It Alone or Partner?

Posted by Renuka Agarwal on Fri, Feb 01, 2019

Ben Hohn, Cody Powers and Judith Kulich co-wrote this article with Renuka Agarwal.

The 2019 JPMorgan Chase Healthcare Conference kicked off with a bang as Eli Lilly announced its acquisition of Loxo Oncology for $8 billion. Loxo, a young biotechnology company that partnered with Bayer to launch its first asset, Vitrakvi, in 2018, isn’t a unique story: In today’s environment, the number of first launches for U.S.-based companies—defined by ZS as the first marketed assets of companies that have FDA “novel” status—is rapidly increasing. There were only three first launches from U.S.-based companies in 2011 compared to an astounding 16 first launches in 2018, primarily in oncology, according to ZS research.


>
Read More

Four Takeaways From the Year’s Biggest—and Rainiest—Healthcare Conference

Posted by Ann Klein on Thu, Jan 31, 2019

Every year in early January, Union Square in San Francisco transforms from a shopping mecca to a (usually rainy) gathering of leadership teams from payers, large providers, life sciences companies and tech companies across the globe. The visual is dramatic: You’ll never see as many dark suits in San Francisco than when you’re wandering around town during the JPMorgan Healthcare Conference.


>
Read More

What the Changes in DTC Spending Mean for Pharma Companies

Posted by Sharon Suchotliff on Mon, Nov 12, 2018

Hensley Evans co-wrote this blog post with Sharon Suchotliff. 

In our previous blog post, we shared three key trends that are driving direct-to-consumer marketing into a state of flux. These forces—the exit of big DTC spenders due to loss of exclusivity, specialty brands driving investment in TV only, and shifts in consumer behavior and marketing mix—are behind the 4.7% decline in spending that we saw between 2016 and 2017.


>
Read More